Results 181 to 190 of about 11,407 (242)

Biosimilar [PDF]

, 2020
openaire   +1 more source

The FDA's adoption of Bayesian methodology: transforming clinical trial justification from biosimilars to broader drug development. [PDF]

Front Med (Lausanne)
Niazi SK.
europepmc   +1 more source

Native Top-Down Mass Spectrometry Combined with High-Resolution Charge Variant Analysis of Trastuzumab Originator and Biosimilars. [PDF]

J Am Soc Mass Spectrom
Beaumal C, Srzentić K, Carillo S, Bones J.   +3 more
europepmc   +1 more source

Net Present Value Impact of FDA's Phase 3 Waivers on Monoclonal Antibody Biosimilar Development. [PDF]

Biologics
Ranbhor R, Kulkarni P.
europepmc   +1 more source

Efficacy and safety of denosumab biosimilars in the treatment of postmenopausal osteoporosis: A systematic review of randomized clinical trials. [PDF]

Clin Exp Med
Shakibaei F, Malekshahi S, Heidari N, Heidari A.   +3 more
europepmc   +1 more source

Safety and Effectiveness of Multi-Switch Between Adalimumab Originator and Biosimilars: A Multicenter (SUSTAIN) Study. [PDF]

J Clin Med
Shehab M, Almajdi A, Abdullah I, Alrashed F.   +3 more
europepmc   +1 more source

An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany. [PDF]

Front Public Health
Raitner I, Müller B, Vijayan A, Zimmermann L, Bramlage P, Ness NH, Müller M.   +6 more
europepmc   +1 more source

Knowledge and Attitude of Aseer Region Pharmacists Toward Biosimilar Medicines: A Descriptive Study. [PDF]

Healthcare (Basel)
Alqahtani S, Almanasef M.
europepmc   +1 more source

Effect of a financial incentive scheme on promoting prescription of biosimilars: a interrupted time-series analyses. [PDF]

Ann Clin Epidemiol
Morita T, Sasabuchi Y, Yasunaga H.
europepmc   +1 more source

Savings from biosimilars and Medicare formulary access. [PDF]

Health Aff Sch
Axelsen K, Courmier D, Bai G, Maini L.
europepmc   +1 more source